Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.

Overview

People Living with HIV-1 (PLHIV) are an important group of patients attending their specialist's and continue growing thanks to efficacy antiretroviral treatment (ART), allowing them to stabilize the HIV-infection and to live a normal life despite the infection. The present study is encouraged to demonstrate that efficacy and security of CAB LA + RPV LA treatment's on this population remains the same compared to younger population of patients. This study also registers some metabolic and hepatic parameters to observe a hypothetical improvement on these parameters, as the population may suffer more comorbidities than younger population and therefore tolerability and convenience gains a huge importance on them. Psychosocial aspects are also very important in these patients as these patients may suffer social stigma, and therefore suffering certain psychological disorders.

Interventions

• Drug Cabotegravir LA + Rilpivirine LA
  Cabotegravir (CAB) LA 600mg and Rilpivirine (RPV) LA 900mg will be administered intramuscularly every 2 months after an induction phase with a single administration in months 1 and 2.

Primary outcome measures

• Numer of patients on stable oral ART that switch to CAB LA + RPV LA with plasma HIV-1 RNA ≥50 copies/mL [Time frame: Up to 12 Months]

Secondary outcome measures (5)

• Levels of HIV-1 RNA Copies [Time frame: 6, 12 and 24 Months]
• Levels of HIV-1 RNA Copies (plasma HIV-1 RNA ≥200 copies/mL) [Time frame: 12 and 24 Months]
• Number of Participants with experienced CVF (confirmed virologic failure) [Time frame: 6, 12 and 24 Months]
• To evaluate the immune effects of switching to CAB LA + RPV LA [Time frame: 6, 12 and 24 Months]
• Number of SAES/SUSAR in patients treated with CAB LA + RPV LA [Time frame: 6, 12 and 24 Months]

Eligibility criteria

Inclusion criteria

• Be able to understand and comply with protocol requirements, instructions, and restrictions.
• Understand the long-term commitment to the study and be likely to complete the study as planned.
• Be considered appropriate candidates for participation in an investigative clinical trial with oral and intramuscularly injectable medications (e.g., no active substance use disorder, acute major organ disease, or planned long-term work assignments out of the country, etc.).
• Must be on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class.
• Plasma HIV-1 RNA <50 copies/mL at screening.
• A female subject is eligible to participate if she is not pregnant (as confirmed by a negative serum hCG test at screen and a negative urine hCG test at randomization) and not lactating

Exclusion criteria

• Plasma HIV-1 RNA measurement ≥50 copies/mL within 6 months prior to screening. Blips are allowed (increased viral load ≥50 copies/mL but <200 copies/mL preceded and followed by a viral load less than 50 copies/mL)
• Any drug holiday during the window between initiating first HIV ART and 6 months prior to screening, except for brief periods (less than 1 month) where all ART was stopped due to tolerability and/or safety concerns.
• Any switch to a second line regimen, defined as change of a single drug or multiple drugs simultaneously, due to virologic failure to NNRTI or INSTI (defined as a confirmed plasma HIV-1 RNA measurement ≥200 copies/mL after initial suppression to <50 copies/mL while on first line HIV therapy regimen)
• Subjects who are currently participating in or anticipate being selected for any other interventional study. Observational studies and intervention studies that do not include treatments are allowed unless they interfere with scheduled visits.
• Participants receiving any prohibited medication and who are unwilling or unable to switch to an alternative medication

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

Spain · 8 centers

• Hospital General Universitario de Elche — Elche
• Hospital Marina Baixa — Villajoyosa
• Hospital General Universitario Santa Lucía — Cartagena
• Hospital Universitario Rafael Mendéz de Lorca — Lorca
• Hospital General Universitario Reina Sofia — Murcia
• Hospital General Universitario Morales Meseguer — Murcia
• Hospital Clinico Universitario Virgen de la Arrixaca Murcia — Murcia
• Hospital General Universitario Los Arcos del Mar Menor — Pozo-Aledo

Identifiers

NCT: NCT06646562 · IMIB-LOVER60-2022-03 · 2022-502882-53-00

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗